Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Ocular Hypertension, Open Angle Glaucoma
Interventions: Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle; Drug · Other
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, Standard of Care; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 66
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more

Conditions: Primary Open Angle Glaucoma
Interventions: iStent, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 14
States / cities: Irvine, California • Montebello, California • Aurora, Colorado + 11 more

Conditions: Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions: MAPLE; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract, Glaucoma, Ocular Hypertension
Interventions: Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL; Drug · Device
Lead sponsor: SpyGlass Pharma, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Latanoprost 0.005%, Latanoprost bunod 0.024%, Normal saline 0.9%, Nailfold capillaroscopy; Drug · Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System (L-PPDS); Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Glaucoma
Interventions: Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Open-Angle Glaucoma
Interventions: AlloSpan Canal Platform Bio-Reinforced Canaloplasty; Procedure
Lead sponsor: Iantrek, Inc.; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 9
States / cities: Chico, California • Petaluma, California • Alexandria, Minnesota + 6 more

Conditions: Ocular Hypertension
Interventions: brimonidine/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Glaucoma, Retinal Disease, Healthy
Interventions: KOWA OCT Bi-µ, Optovue iVue 100; Device
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Glaucoma, Glaucoma, Open-Angle
Interventions: AqueSys Microfistula Implant; Device
Lead sponsor: AqueSys, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 14
States / cities: Fayetteville, Arkansas • Los Angeles, California • San Diego, California + 11 more

Conditions: Glaucoma, Open-Angle, Glaucoma; Drugs
Interventions: dorzolamide/timolol; Drug
Lead sponsor: CT Glaucoma Associates; Other
Eligibility: 25 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Norwalk, Connecticut

Conditions: Normal Tension Glaucoma
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years to 101 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: ALS, Autism Spectrum Disorder, Cancer, Spasticity, Muscle, Dyskinetic Syndrome, Epilepsy, Glaucoma, Huntington Disease, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Neuropathy, Opioid Use, Parkinson Disease, HIV/AIDS, Ptsd, Intractable Pain, Sickle Cell Disease, Terminal Illness
Interventions: Registry, PK microsampling of blood; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma, Open-Angle, Glaucoma
Interventions: iStent Inject Implantation; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Phoenix, Arizona • Torrance, California • Dallas, Texas

Conditions: Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions: brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution; Drug · Other
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2036
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Glaucoma, Open-Angle, Failing Bleb Following Trabeculectomy
Interventions: Ranibizumab (Lucentis); Drug
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 40 Years and older
Enrollment: 6 participants
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions: Cannabis, Medical, RYAH-Medtech Inhaler; Drug · Device
Lead sponsor: OMNI Medical Services, LLC; Network
Eligibility: 7 Years and older
Enrollment: 200,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more

Conditions: Glaucoma
Interventions: OrCam; Device
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Ahmed FP7 Valve, Baerveldt-350 Tube; Device
Lead sponsor: Credit Valley EyeCare; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution; Drug
Lead sponsor: Aerpio Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 2
States / cities: Austin, Texas • Dallas, Texas

Conditions: Glaucoma, Open-Angle
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

Study of an Intervention to Improve Problem List Accuracy and Use

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Nailfold Capillary Blood Flow With Latanoprost Bunod

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

Topical Insulin for Glaucoma

A Study of Outcomes Following Bio-Reinforced Canaloplasty in Eyes With Open-Angle Glaucoma

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100

AqueSys Microfistula Implant in Refractory Glaucoma

How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?

A New View of Normal Tension Glaucoma: Autoregulation and Systemic Blood Pressure

Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

iStent Inject New Enrollment Post-Approval Study

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

Treatment of Failing Blebs With Ranibizumab

Outcomes Mandate National Integration With Cannabis as Medicine

Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?

The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation